Connect with us

Medtech

Apple gets an appeals court win for its Apple Watch

Apple has at least a couple more weeks before it has to worry about another sales ban.

Published

on

This article was originally published by TheStreet

It has been quite the roller coaster ride for Apple  (AAPL) – Get Free Report over the past couple of days as the company fights to sell one of its most popular products in the U.S. 

On Wednesday, the company won a temporary pause of a sales ban on the Apple Watch that went into effect on Tuesday. 

Related: Why Apple is pausing sales of its newest Apple Watch

A patent dispute with medical device maker Masimo  (MASI) – Get Free Report led the U.S. International Trade Commission to ban the sale of the device in the States, but a federal appeals court ordered that the sales ban be paused following a request from Apple.

Apple wants U.S. Customs to review changes the company has made to see whether they will be enough to avoid infringing on any existing patents. The company filed an emergency request with the U.S. Court of Appeals for the Federal Circuit Tuesday.  

The ITC ruled in October that Apple was in violation of Masimo’s patent for technology used in its pulse oximeter (the thing that measures the oxygen level of the blood). But Apple wants until at least Jan. 12 when U.S. Customs is expected to review its changes and make a decision. 

The stay means Apple can resume selling the watch after pulling the Apple Watch Series 9 and Apple Watch Ultra 2 from its website last week and from in-store shelves earlier this week. 

The Apple Watch is displayed at an Apple Store on Nov. 2 in Corte Madera, Calif. (Photo by Justin Sullivan/Getty Images)

Justin Sullivan/Getty Images

Masimo’s CEO has said that Apple’s use of the technology is a “deliberate infringement” of its patent. Apple started selling Apple Watches with pulse oximeters starting in 2020. 

Apple’s wearables, home and accessories segment saw revenue of nearly $40 billion in fiscal 2023, which was a decline from the more than $41 billion the segment generated in fiscal 2022. 

While the Apple Watch is only one big part of wearables, the business segment is a bigger revenue generator than both the iPad ($28.3 billion) and Mac ($29.4 billion) for Apple. 

So the stakes are big for the tech giant that is the world’s most valuable company with a nearly $3 trillion market cap. 

Masimo shares were down 5.7% at last check on the news Wednesday afternoon while Apple shares were basically unchanged. 

Want to turbocharge your portfolio? Learn from the investing legends and get actionable insights. Start your Real Money Pro membership today. 

medical
device
shares
sell

Medtech

ETF Talk: AI is ‘Big Generator’

Second nature comes alive Even if you close your eyes We exist through this strange device — Yes, “Big Generator” Artificial intelligence (AI) has…

Continue Reading
Markets

Federal court blocks ban on Apple Watches after Apple appeal

A federal appeals court has temporarily blocked a sweeping import ban on Apple’s latest smartwatches while the patent dispute winds its way through…

Continue Reading
Medtech

AI can already diagnose depression better than a doctor and tell you which treatment is best

Artificial intelligence (AI) shows great promise in revolutionizing the diagnosis and treatment of depression, offering more accurate diagnoses and predicting…

Continue Reading

Trending

Apple gets an appeals court win for its Apple Watch

Apple has at least a couple more weeks before it has to worry about another sales ban.

Published

on

This article was originally published by TheStreet

It has been quite the roller coaster ride for Apple  (AAPL) – Get Free Report over the past couple of days as the company fights to sell one of its most popular products in the U.S. 

On Wednesday, the company won a temporary pause of a sales ban on the Apple Watch that went into effect on Tuesday. 

Related: Why Apple is pausing sales of its newest Apple Watch

A patent dispute with medical device maker Masimo  (MASI) – Get Free Report led the U.S. International Trade Commission to ban the sale of the device in the States, but a federal appeals court ordered that the sales ban be paused following a request from Apple.

Apple wants U.S. Customs to review changes the company has made to see whether they will be enough to avoid infringing on any existing patents. The company filed an emergency request with the U.S. Court of Appeals for the Federal Circuit Tuesday.  

The ITC ruled in October that Apple was in violation of Masimo’s patent for technology used in its pulse oximeter (the thing that measures the oxygen level of the blood). But Apple wants until at least Jan. 12 when U.S. Customs is expected to review its changes and make a decision. 

The stay means Apple can resume selling the watch after pulling the Apple Watch Series 9 and Apple Watch Ultra 2 from its website last week and from in-store shelves earlier this week. 

The Apple Watch is displayed at an Apple Store on Nov. 2 in Corte Madera, Calif. (Photo by Justin Sullivan/Getty Images)

Justin Sullivan/Getty Images

Masimo’s CEO has said that Apple’s use of the technology is a “deliberate infringement” of its patent. Apple started selling Apple Watches with pulse oximeters starting in 2020. 

Apple’s wearables, home and accessories segment saw revenue of nearly $40 billion in fiscal 2023, which was a decline from the more than $41 billion the segment generated in fiscal 2022. 

While the Apple Watch is only one big part of wearables, the business segment is a bigger revenue generator than both the iPad ($28.3 billion) and Mac ($29.4 billion) for Apple. 

So the stakes are big for the tech giant that is the world’s most valuable company with a nearly $3 trillion market cap. 

Masimo shares were down 5.7% at last check on the news Wednesday afternoon while Apple shares were basically unchanged. 

Want to turbocharge your portfolio? Learn from the investing legends and get actionable insights. Start your Real Money Pro membership today. 



shares
sell

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Markets

Seducing stocks: Canoo Inc (NASDAQ:GOEV 5.43%), Ginkgo Bioworks Holdings Inc (NYSE:DNA -1.12%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading

Trending